A broad product range

The Generic business operates under the West-ward label, selling 46 non-branded solid generics in 97 dosage strengths and forms. Although these span a variety of indications, we focus on the CNS, cardiovascular, anti-infective and musculoskeletal therapeutic areas.

Our strong pipeline

The Generic business has 31 ANDAs awaiting FDA approval, including 23 new compounds not previously marketed by us. We also have nearly 40 new products under development, primarily in the cardiovascular, CNS and alimentary therapeutic categories.

Significant customer base

We have more than 250 customers, including pharmaceutical wholesalers and distributors, as well as large retail chains. Our US sales and marketing representatives have been trained and aligned to meet the needs of these different types of customers.